9.45 -0.4 (-4.06%) | 02-12 19:07 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 14.08 | 1-year : | 17.12 |
Resists | First : | 12.06 | Second : | 14.65 |
Pivot price | 10.94 ![]() |
|||
Supports | First : | 7.86 | Second : | 6.53 |
MAs | MA(5) : | 11.06 ![]() |
MA(20) : | 10.72 ![]() |
MA(100) : | 9.56 ![]() |
MA(250) : | 9.93 ![]() |
|
MACD | MACD : | 0.3 ![]() |
Signal : | 0.5 ![]() |
%K %D | K(14,3) : | 29 ![]() |
D(3) : | 45.8 ![]() |
RSI | RSI(14): 44 ![]() |
|||
52-week | High : | 16.64 | Low : | 6.32 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ORIC ] has closed above bottom band by 8.6%. Bollinger Bands are 52.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 9.7 - 9.77 | 9.77 - 9.82 |
Low: | 8.57 - 8.65 | 8.65 - 8.72 |
Close: | 9.32 - 9.45 | 9.45 - 9.54 |
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Wed, 12 Feb 2025
ORIC Pharmaceuticals stock target holds at $21 by H.C. Wainwright - MSN
Tue, 11 Feb 2025
ORIC Pharmaceuticals (NASDAQ:ORIC) Earns Buy Rating from HC Wainwright - MarketBeat
Mon, 10 Feb 2025
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 14.7% - Time to Buy? - MarketBeat
Mon, 10 Feb 2025
ORIC Pharmaceuticals shares surge on potential data leak - MSN
Mon, 10 Feb 2025
ORIC Pharmaceuticals shares surge on potential data leak - Investing.com
Fri, 07 Feb 2025
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 71 (M) |
Shares Float | 43 (M) |
Held by Insiders | 9.5 (%) |
Held by Institutions | 102.2 (%) |
Shares Short | 10,520 (K) |
Shares Short P.Month | 11,210 (K) |
EPS | -1.83 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 3.88 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -29.3 % |
Return on Equity (ttm) | -46 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -1.9 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -109 (M) |
Levered Free Cash Flow | -65 (M) |
PE Ratio | -5.2 |
PEG Ratio | 0 |
Price to Book value | 2.43 |
Price to Sales | 0 |
Price to Cash Flow | -6.13 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |